Increased Matrix Metalloproteinase-2 Expression and Reduced Tissue Factor Pathway Inhibitor-2 Expression Correlate with Angiogenesis and Early Postoperative Recurrence of Pancreatic Carcinoma

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2016 Jan 26

PMID 26807187

Citations 14

Authors

Lu-Lu Zhai

Yang Wu

Da-Wei Huang

Zhi-Gang Tang

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinase (MMP)-2 and tissue factor pathway inhibitor (TFPI)-2 are known to influence tumor angiogenesis and progression. This work aimed to describe the levels of MMP-2 and TFPI-2 expression associated with tumor angiogenesis and early postoperative recurrence in patients with pancreatic carcinoma. Expression of MMP-2 and TFPI-2 in carcinoma tissues and paracarcinomatous tissues was assayed by immunostaining. Expression of vascular endothelial growth factor (VEGF) and CD34 in tumor tissues was also assayed by immunostaining. The correlations of MMP-2 and TFPI-2 with VEGF, microvessel density (MVD), and early postoperative recurrence were analyzed. The results showed that MMP-2 expression was significantly increased (P < 0.05) and TFPI-2 expression was significantly decreased (P < 0.001) in carcinoma tissues compared with paracarcinomatous tissues. MMP-2 expression was positively correlated with VEGF (r = 0.594, P < 0.001) and MVD (r = 0.432, P < 0.001) in carcinoma tissues. TFPI-2 expression was negatively correlated with VEGF (r = -0.654, P < 0.001) and MVD (r = -0.360, P < 0.001) in carcinoma tissues. Multivariate logistic regression analysis showed that up-regulated MMP-2 and down-regulated TFPI-2 were independent predictors of early postoperative recurrence of pancreatic carcinoma. Receiver operating characteristic curve analysis showed that the combination of MMP-2 and TFPI-2 was a reliable predictive model of early recurrence. We conclude that increased MMP-2 expression and reduced TFPI-2 expression are closely linked to angiogenesis and early postoperative recurrence of pancreatic carcinoma. Immunohistochemical assay of MMP-2 and TFPI-2 may be useful for predicting early relapse of pancreatic carcinoma after surgery.

Citing Articles

Curcumin inhibits the invasion and migration of pancreatic cancer cells by upregulating TFPI-2 to regulate ERK- and JNK-mediated epithelial-mesenchymal transition.

Zhai L, Li W, Chen L, Wang W, Ju T, Yin D Eur J Nutr. 2023; 63(2):639-651.

PMID: 38129361 DOI: 10.1007/s00394-023-03296-5.

A new scoring system with simple preoperative parameters as predictors of early recurrence of pancreatic ductal adenocarcinoma.

Shimagaki T, Sugimachi K, Mano Y, Tomino T, Onishi E, Nakashima Y PLoS One. 2023; 18(7):e0288033.

PMID: 37450554 PMC: 10348551. DOI: 10.1371/journal.pone.0288033.

Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma.

Nappo G, Donisi G, Capretti G, Ridolfi C, Pagnanelli M, Nebbia M Curr Oncol. 2023; 30(4):3708-3720.

PMID: 37185395 PMC: 10137113. DOI: 10.3390/curroncol30040282.

Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.

Murata Y, Ogura T, Hayasaki A, Gyoten K, Ito T, Iizawa Y PLoS One. 2022; 17(4):e0264573.

PMID: 35377885 PMC: 8979444. DOI: 10.1371/journal.pone.0264573.

Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.

Ishido K, Kimura N, Wakiya T, Nagase H, Hara Y, Kanda T Ann Surg Oncol. 2021; 29(2):1281-1293.

PMID: 34608555 PMC: 8724152. DOI: 10.1245/s10434-021-10866-6.

References

Udagawa K, Yasumitsu H, Esaki M, Sawada H, Nagashima Y, Aoki I . Subcellular localization of PP5/TFPI-2 in human placenta: a possible role of PP5/TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts. Placenta. 2002; 23(2-3):145-53. DOI: 10.1053/plac.2001.0774. View

Zhai L, Cai C, Wu Y, Tang Z . Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma. Int J Clin Exp Pathol. 2015; 8(1):682-91. PMC: 4348899. View

Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton H, Rodriguez-Aguayo C, Fernandez-de Thomas R . Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res. 2015; 21(9):2127-37. PMC: 4417466. DOI: 10.1158/1078-0432.CCR-14-2279. View

Herman M, Sukhova G, Kisiel W, Foster D, Kehry M, Libby P . Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest. 2001; 107(9):1117-26. PMC: 209273. DOI: 10.1172/JCI10403. View

Gong Z, Holly E, Bracci P . Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol. 2011; 174(12):1373-81. PMC: 3276299. DOI: 10.1093/aje/kwr267. View

Zhang Q, Zhang Y, Wang S, Wang N, Jiang W, Ji Y . Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer. J Exp Clin Cancer Res. 2012; 31:1. PMC: 3314549. DOI: 10.1186/1756-9966-31-1. View

Aparna M, Rao L, Kunhikatta V, Radhakrishnan R . The role of MMP-2 and MMP-9 as prognostic markers in the early stages of tongue squamous cell carcinoma. J Oral Pathol Med. 2014; 44(5):345-52. DOI: 10.1111/jop.12245. View

Jiang P, Watanabe H, Okada G, Ohtsubo K, Mouri H, Tsuchiyama T . Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Sci. 2006; 97(11):1267-73. PMC: 11158502. DOI: 10.1111/j.1349-7006.2006.00308.x. View

Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G . CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther. 2006; 5(7):808-14. DOI: 10.4161/cbt.5.7.2754. View

10.

Maatta M, Soini Y, Liakka A, Autio-Harmainen H . Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res. 2000; 6(7):2726-34. View

11.

Gessler F, Voss V, Seifert V, Gerlach R, Kogel D . Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci Lett. 2011; 497(1):49-54. DOI: 10.1016/j.neulet.2011.04.027. View

12.

Izumi H, Takahashi C, Oh J, Noda M . Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett. 2000; 481(1):31-6. DOI: 10.1016/s0014-5793(00)01902-5. View

13.

Suh Y, Lee E, Cha H, Yang S, Seong J . Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy. Dig Dis. 2014; 32(6):725-32. DOI: 10.1159/000368010. View

14.

Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H . Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006; 26(5A):3579-83. View

15.

Ekinci T, Ozun Ozbay P, Yigit S, Yavuzcan A, Uysal S, Soylu F . The correlation between immunohistochemical expression of MMP-2 and the prognosis of epithelial ovarian cancer. Ginekol Pol. 2014; 85(2):121-30. DOI: 10.17772/gp/1702. View

16.

Yoshizaki T, Maruyama Y, Sato H, Furukawa M . Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer. 2001; 95(1):44-50. DOI: 10.1002/1097-0215(20010120)95:1<44::aid-ijc1008>3.0.co;2-m. View

17.

Rao C, Reddy P, Liu Y, OToole E, Reeder D, Foster D . Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys. 1996; 335(1):82-92. DOI: 10.1006/abbi.1996.0484. View

18.

Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S . Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. Pancreatology. 2014; 14(6):524-9. DOI: 10.1016/j.pan.2014.09.006. View

19.

Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G . Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A. 2000; 97(8):3884-9. PMC: 18111. DOI: 10.1073/pnas.97.8.3884. View

20.

Ellenrieder V, Alber B, Lacher U, Hendler S, Menke A, Boeck W . Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer. 1999; 85(1):14-20. DOI: 10.1002/(sici)1097-0215(20000101)85:1<14::aid-ijc3>3.0.co;2-o. View